New GMP Guidelines Spark Active M&As In Wuhan
This article was originally published in PharmAsia News
Executive Summary
China's new GMP guidelines will soon spark a parade of M&As in Wuhan where the majority of drug companies are small- to medium-sized, said Jiuan Wuhan Pharmaceutical's director Zhang Weicheng